7W3 Stock Overview
Operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Acotec Scientific Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.75 |
| 52 Week High | HK$1.33 |
| 52 Week Low | HK$0.69 |
| Beta | 0.22 |
| 1 Month Change | -11.24% |
| 3 Month Change | -7.98% |
| 1 Year Change | -38.02% |
| 3 Year Change | -39.02% |
| 5 Year Change | n/a |
| Change since IPO | -61.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7W3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -2.9% | -2.6% |
| 1Y | -38.0% | -8.5% | 6.9% |
Return vs Industry: 7W3 underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 7W3 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 7W3 volatility | |
|---|---|
| 7W3 Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7W3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7W3's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 615 | Jing Li | www.acotec.cn |
Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China, Europe, and internationally. The company’s products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery (SFA) and popliteal artery (PPA) for the treatment of lower extremity artery disease (LEAD) with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee (BTK) arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices targeting vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; Peripheral Aspiration System (AcoStream); Radiofrequency Ablation System (AcoArt Cedar); Peripheral Support Catheter (Vericor); The PTA Balloon (P-Conic); and 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream).
Acotec Scientific Holdings Limited Fundamentals Summary
| 7W3 fundamental statistics | |
|---|---|
| Market cap | €240.65m |
| Earnings (TTM) | €4.21m |
| Revenue (TTM) | €68.72m |
57.1x
P/E Ratio3.5x
P/S RatioIs 7W3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7W3 income statement (TTM) | |
|---|---|
| Revenue | CN¥523.12m |
| Cost of Revenue | CN¥123.62m |
| Gross Profit | CN¥399.51m |
| Other Expenses | CN¥367.43m |
| Earnings | CN¥32.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 76.37% |
| Net Profit Margin | 6.13% |
| Debt/Equity Ratio | 4.1% |
How did 7W3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acotec Scientific Holdings Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Yu | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |
| Yiling Chen | Guosen Securities Co., Ltd. |